These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33197349)

  • 21. Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.
    Zaccardi F; Kloecker DE; Khunti K; Davies MJ
    Diabetes Obes Metab; 2022 Aug; 24(8):1598-1606. PubMed ID: 35491523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
    Escobar Cervantes C
    Lancet Diabetes Endocrinol; 2024 Aug; 12(8):507-508. PubMed ID: 38991583
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 25. GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.
    Aroda VR; Billings LK
    J Am Coll Cardiol; 2023 Aug; 82(6):526-528. PubMed ID: 37532423
    [No Abstract]   [Full Text] [Related]  

  • 26. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.
    Cai X; Ji L; Chen Y; Yang W; Zhou L; Han X; Zhang S; Ji L
    J Diabetes Investig; 2017 Jul; 8(4):510-517. PubMed ID: 28106956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes.
    Nonomura K; Iizuka K; Kuwabara-Ohmura Y; Yabe D
    Intern Med; 2020 Jun; 59(12):1535-1539. PubMed ID: 32188813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Liu M; Hao G
    Eur J Prev Cardiol; 2023 Jun; 30(8):656-657. PubMed ID: 36740456
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
    DeFronzo RA
    Diabetes Obes Metab; 2017 Oct; 19(10):1353-1362. PubMed ID: 28432726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
    Meade LT; Mannka ML
    Ann Pharmacother; 2019 Nov; 53(11):1111-1116. PubMed ID: 31215219
    [No Abstract]   [Full Text] [Related]  

  • 33. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond.
    Kloecker DE; Davies MJ; Khunti K; Zaccardi F
    Diabetes Obes Metab; 2021 Jul; 23(7):1685-1691. PubMed ID: 33764645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Indications of antidiabetic drugs beyond glucose control].
    Hartmann NK; Lehrke M
    MMW Fortschr Med; 2023 Mar; 165(5):42-49. PubMed ID: 36894856
    [No Abstract]   [Full Text] [Related]  

  • 37. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
    Hocher B; Tsuprykov O
    Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
    [No Abstract]   [Full Text] [Related]  

  • 39. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.